Boehringer Ingelheim has revealed further details about its plans for a new kind of cancer immunotherapy licensed in from biotech OSE Therapeutics at the beginning of last month, saying it
Merck & Co's cancer drug Keytruda has been granted a priority review so that the immunotherapy medicine can be used in conjunction with chemotherapy to improve survival rates for untrea
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
